Business Wire

Aimbridge Hospitality and Interstate Hotels & Resorts to Merge

Share

Aimbridge Hospitality (“Aimbridge”), North America’s largest independent hotel management firm, and Interstate Hotels & Resorts (“Interstate”), a leading independent multinational hotel operator, announced today that they have entered into a definitive agreement to merge, creating a global leader in third-party hotel management services. The combined company will manage a portfolio of more than 1,400 branded and independent properties in 49 states and 20 countries. Terms of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190829005589/en/

Together, it is expected that Aimbridge and Interstate will have the scale, resources and global reach to reinforce their leading hospitality offerings, continue delivering superior financial and investment performance for hotel partners and create positive experiences for guests. Hotel owners will benefit from a scaled, global platform; enhanced data and analytic capabilities; a top talent pool; and increased support and resources, including sales, marketing, ecommerce and revenue management infrastructure. This enhanced offering will position the combined company for further growth and international expansion.

Dave Johnson, Co-Founder and CEO of Aimbridge, will become CEO of the combined business. Michael Deitemeyer, President and CEO of Interstate, will become Global President, overseeing operations globally and corporate disciplines. The merged company will be a premier employer in the hospitality industry, with a talent pool of more than 60,000 employees delivering best-in-class service worldwide.

“Aimbridge is thrilled about the opportunity to join forces with Interstate to enable us to bring even more value to our hotel owners,” said Dave Johnson, Co-Founder and CEO of Aimbridge. “Our combined scale will ensure access to more robust data and the best talent to further differentiate us as leading hospitality managers. Personally, I am excited to work with Mike Deitemeyer, a good friend and well-respected industry leader.”

“Our united, global portfolio allows us the talent and expertise to ensure we deliver best-in-class operations across all hospitality product categories,” said Mike Deitemeyer, President and CEO of Interstate. “Dave and I share a common focus on winning through our people.”

Advent International, one of the largest and most experienced global private equity investors, acquired a majority ownership stake in Aimbridge earlier this year and will assume majority ownership of the combined entity.

“Through this merger and under Advent’s ownership, Aimbridge and Interstate can build a platform that differentiates the combined company through optimizing owner value, top-notch talent and global expansion,” said Glenn Murphy, Chairman, Aimbridge.

“We have enjoyed our valuable partnership with Mike Deitemeyer and the Interstate team and appreciate their efforts in establishing Interstate as a global leader in the third-party hotel management sector,” said Ahmed I. Wahla, Partner at Kohlberg & Company, which has owned Interstate since 2016.

The transaction is subject to regulatory approval and customary closing conditions. It is expected to be completed by the end of 2019.

Goldman Sachs & Co. LLC and Moelis & Company LLC acted as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to Interstate. Ropes & Gray LLP acted as legal advisor to Aimbridge.

About Aimbridge Hospitality

Aimbridge is the nation’s largest independent hotel management firm with a proven track record for delivering superior returns for its strategic partners in a variety of markets and through economic cycles. Aimbridge provides hotel management services, accounting, revenue management, and a full suite of services. Based in Dallas, Texas, Aimbridge currently manages approximately 800 hotels with more than 100,000 rooms across the United States, Canada and the Caribbean. For more information, visit www.aimbridgehospitality.com.

About Interstate Hotels & Resorts

Interstate is a leading, global, third-party hotel management company, operating branded full service, select service, luxury hotels, destination resorts, convention centers and lifestyle hotels. Currently, Interstate’s global portfolio represents 600 properties in 15 countries inclusive of a committed pipeline of hotels under construction or development around the world. The company’s experienced operators, industry-leading platforms and extensive management capabilities produce exceptional guest experiences and optimal returns for hotel owners and investors. For more information, please visit www.interstatehotels.com.

About Advent International

Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 345 private equity transactions in 41 countries, and as of March 31, 2019, had $36 billion in assets under management, which does not include the $17.5 billion recently raised for its ninth global fund, GPE IX. With offices on four continents, Advent has established a globally integrated team of over 195 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; health care; industrial; retail, consumer and leisure; and technology, media and telecom. After 35 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies. For more information, visit: www.adventinternational.com.

About Kohlberg & Company

Kohlberg & Company, LLC (“Kohlberg”) is a leading private equity firm headquartered in New York. Since its inception in 1987, Kohlberg has organized eight private equity funds, through which it has raised over $7.5 billion of committed equity capital. Over its 32-year history, Kohlberg has completed 80 platform investments and nearly 200 add-on acquisitions, with an aggregate transaction value of over $20 billion. For more information visit: www.kohlberg.com.

###

Contact information

Media Contacts

Aimbridge
Kellie McCrory, MCA Public Relations
kellie@mcaprgroup.com
+1 (214) 654-0402

Interstate
Kerry Anne Watson, The Zimmerman Agency
kwatson@zimmerman.com
+1 (850) 668-2222

Taylor Schillace, The Zimmerman Agency
tschillace@zimmerman.com
+1 (813) 784-0682

For UK/International:
Kirstie Nickson or Eve Worthington, Sidekick PR
info@sidekickpr.com
+44 7714 822919

Advent International
Kerry Golds or Patrick Reynolds, Finsbury
adventinternational-US@finsbury.com
+1 (646) 805-2000

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

 Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 16:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met

RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 13:30:00 CESTPress release

On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 12:00:00 CESTPress release

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past

Visa B2B Connect Expands to 32 New Countries and Announces Integration With Infosys20.9.2019 11:00:00 CESTPress release

Visa Inc. (NYSE:V) today announced that its Visa B2B Connect network has doubled its reach – from 30 global trade corridors at launch in June 2019, to 62, with the goal to expand to over 100 countries in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005082/en/ Visa B2B Connect (Graphic: Business Wire) In addition, Infosys, a global leader in next-generation digital services and consulting, is integrating with the Visa B2B Connect network to bring Visa B2B Connect platform access to their participating financial institutions worldwide. Through this new connection, participating financial institutions worldwide can take advantage of the ability to quickly and securely process corporate cross-border payments globally through Visa B2B Connect.1 “Visa B2B Connect is a fast, secure and more efficient network, designed specifically to overcome obstacles in the cross-border corporate payments space,” said Alan Koenigsbe

Open Day at ISAE-SUPAERO!20.9.2019 09:53:00 CESTPress release

As part of the Science Festival, this year organized on the theme of “Talking about Science, Imagining the Future”, ISAE-SUPAERO will open up its entire campus to the public on Saturday, October 12th from 10 am to 6 pm. Intended for families, companies, partners, journalists and alumni, this event should bring in over 3,000 attendees, as was the case in the three previous years! The program for the day includes many opportunities to discover science today and our vision of the science of the future, with the challenges this entails for the future of our planet. On the program: ➢ Visits to the laboratories and research departments with flight simulators ➢ Visit to the aeroacoustic wind tunnel, unique in Europe, ➢ Demonstrations: how to fly an airplane, Enoskelet, augmented humans, aeroelasticity, drones, use of the gyroscopic effect in space systems, piezoelectric effect, lasers for communicating at the speed of light on Earth and in space, the infinitely small in 3D, Robot Firefighter

William Priest to Step Down as CEO in 2020, Will Remain at Firm as Executive Chairman and Co-CIO20.9.2019 07:00:00 CESTPress release

Epoch Investment Partners, Inc., announced that William Priest will step down as the firm's CEO effective April 1, 2020. He will become Epoch's Executive Chairman and will continue to lead the investment team and serve as co-CIO. He will also retain his portfolio management responsibilities, including his lead portfolio manager role with Epoch's Global Choice and Global Absolute Return strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005076/en/ Philipp Hensler (Photo: Business Wire) Philipp Hensler, Epoch's President and COO, will become the firm's CEO. Hensler brings to the role extensive leadership experience at asset management firms globally. His earlier background as a portfolio manager has imbued him with an investment-oriented perspective that aligns with Epoch's investment-centric culture. “Investing remains my lifelong passion," said Priest, who helped found Epoch in 2004. “Best practice suggests a s